Abstract
Subject Index
Acute myeloid leukemia, 193-203
Adenovirus, 349
Aequorin, 30-41
A-427 human cancer cells, 56-66
Alexa Fluor 680, 171-179
Alzheimer's disease, 348, 361, 362, 363
Angiogenesis, 289-295, 331-338, 340, 344, 354
Animal imaging scanners, 108-119, 343
Anti-claudin 4, 131-139
Anti-intercellular adhesion molecule 1 antibody, 75-83
Anti-prostate stem cell antigen, 131-139
Apoptosis, 158, 417-425
Aptamers, 351
Arthritic inflammation, 347
Ataxia, 361
Atheroma, 347
Atherosclerosis, 247-259, 347, 355, 356
Autoimmune disease, 364-365
Bacteriochlorophyll, 240, 241-242
Beta-galactosidase, 219-227
Bioluminescence, 346, 366
activity measurement, 221
of BDC cell trafficking patterns, 371-373
imaging of brain tumor, 340
imaging of lentiviral stem cells, 344
imaging of tumor cell growth, 315-322
imaging of vascular endothelial growth factor promoter activity, 331-338
INTEGRIM tool, 345
in vivo visualization of antitumor effects, 297-303
of luciferase reporters, 121-130
of mammalian cells, 323-329
of Period1 gene, 68-71
red-shifted aequorin-based, 30-41
in stem cell-based bone formation, 347
Bombesin, 171-179
Bone
formation, 347
marrow, 344, 362
metastases, 350
Bone morphogenetic protein 7, 345
Bowel imaging, 346
Brain, 341
abnormal, 362
injury, 156-168, 348
metabolism, 346
metachromatic leukodystrophy, 344
repair, 342
tumor, 181-191, 340
Breast cancer, 171-179, 205-210, 334, 348, 350, 352
Bruker MR imaging, 111, 117
Calcium, 30-41
Cancer, 342, 349-355
A-427 cells, 56-66
breast, 171-179, 205-210, 334, 348, 350, 352
colorectal, 352, 365
DNA vaccine, 297-303
lung, 353, 355
pancreatic, 131-139
prostate, 10-16, 277-287, 349, 351
tracers for, 43-54
See also Tumor(s)
Carbon nanotubes, 340
Carcinomas, 18-27
Cardiac arrest, 156-168
Cardiac micro-computed tomography, 261-268
Cardiovascular disease, 340
Cardiovascular imaging, 355-356
Catheters, 147-155
CD4+ T cells, 369-382
Cell internalization, 1-8
Cellular function, 30-41
Cellular imaging, 342, 344
Cellular labeling, 357
C57Black6 mice, 156-168
Chemotherapy, 353, 355
Chondrosarcoma, 351
Clathrin-mediated endocytosis, 279, 284
Claudin 4, 131-139
Click-chemistry, 344
CLINDE, 347
Cluster analysis, 366
c-MET antigen, 18-27
CNA35 marker, 247-259
Collagen, 247-259, 343
Collagen sponge matrices, 323-329
Colorectal cancer, 352, 365
Confocal fluorescence microscopy, 87, 140-145
Confocal laser scanning microscopy, 342
Cy5-labeled RAFT-c(-RGDfK-)4, 43-54
Cyclosporin A, 361
Cytokines, 299-301
Dementia, 341
Depression, 341
Dextran, 1-8
Diabetes, 369-382
DNA cancer vaccine, 297-303
DNA fragmentation, 156-168
Dopamine, 359, 360, 362, 363
Drugs, 340, 349
D2R80A receptor, 183-187
Dynamic measurement approach, 315-322
Edema, 156-168
Emission bandpass imaging, 271
Endocrine neoplasia, 348
Endoscopy, 147-155
Endothelial cells, 79, 81, 354
Epidermal growth factor receptor, 342
Epifluorescent continuous-wave single excitation imaging, 271
Esophageal anastomosis, 345
Estrogen, 363
Exogenous gene expression, 181-191
Factor analysis, 354
fDOT, 345
Femorotibial cartilage, 346
Feridex IV, 1-8
Fetus, 68-71
Fibered confocal fluorescence microscopy, 140-145
Fixed geometry intraoperative systems, 147-155
Flow cytometry, 57, 98, 278, 374
Flow-focusing chambers, 385
Fluorescence-activated cell sorting, 316
Fluorescence lifetime imaging
discrimination based on, 304-313
for in vivo studies, 229-235
ear-infrared molecular probes by, 237-245
Fluorescence microscopy, 140-145, 173-174
Fluorescence molecular tomography, 96-105, 345, 367
Fluorescence reflectance imaging, 366
Fluorescent ligands, 360
Fluorescently labeled CNA35 marker, 247-259
Fluoride-18, 343
Fluorine-18, 344, 359
Forebrain ischemia-reperfusion, 156-168
Gadolinium, 344, 357, 358, 359
Gadolinium
diethylenetriaminepentaacetic acid, 75-83
Gastrin-releasing peptide, 171-179
Gefitinib, 350
Glioblastoma, 351
Glioma, 181-191, 343, 344, 345, 353
Globoid cell leukodystrophy, 362
Glucose, 350
Glutamine, 358
Graft-versus-host disease, 345
Green fluorescent protein, 96-105, 193-203, 269-276
Heat shock proteins, 404-414
Hepatocarcinogenesis, 18-27
Herpes simplex, 181-191
High-resolution multipinhole single-photon computed tomography, 347
Hodgkin's lymphoma, 355
HSP70-inducible hNIS-IRES-eGFP reporter imaging, 404-414
Human MUC1 vaccination, 297-303
Huntington disease, 343
Hypoxia, 219-227, 331, 333
Immune system, 362
Immunoblot analysis, 77, 406-407
Immunocytochemical staining, 406-407
Immunofluorescence, 132-133, 134, 428
Immunohistochemistry, 3, 77, 290
Inflammation
arthritic, 347
MRI of, 346
targeted T1 contrast agents, 75-83
T cell-mediated, 369-382
tumor versus imaging, 364
Infrared-excited multiphoton microscopy, 354
Insulitis, 369-382
INTEGRIM, 345
Integrin, 43-54
Internalization assay, 58, 60
Intraliposomal water protons, 357
Intraoperative fluorescence reflectance imager, 354
Intraoperative molecular imaging, 340
Iron oxide, 277-287, 349, 356, 358, 360, 365
Ischemia, 156-168, 304-313, 342, 343
Ischemic penumbra, 341
Kidneys, 304-313
LacZ, 219-227
Lanthanide, 344
Laser scanning microscopy, 247-259
Leukemia, 193-203
Ligands, 360
Lipofectamine, 1-8
Liposomes, 85-94, 140-145, 343, 358, 365, 417-425
Liver, 346
Luciferase, 71, 121-130, 219-227, 323-329
Lung tumor/cancer, 345, 353, 355
Lymphoid organs, 340
Lymphoma, 353
Magnetic nanoparticles, 1-8, 277-287
Magnetic resonance imaging (MRI)
of bowel, 346
cellular, 342
of c-MET expression, 18-27
contrast-enhanced, 347, 357, 393-402
detection of early tumor responses, 341
detection of matrix metalloproteinase activity, 393-402
for image-guided drug delivery, 340
of inflammatory tissues, 75-83, 346
iron oxide colloids for, 358
magnetic labeling of cells, 212-218
with metachromatic leukodystrophy, 344
anosized, 341
perfusion and diffusion, 351
for solid tumor xenografts, 85-94
targeting tumors with, 349
Magnetic resonance spectroscopy, 341, 353, 354
Mammalian cells, 323-329
Mammary gland, 205-210
Mammary tumorigenesis, 331-338
Matrix metalloproteinase activity, 393-402
Medications. See Drugs
Melanoma, 353
Melanoma pulmonary metastases, 350
Metachromatic leukodystrophy, 344
Metalloproteinase activity, 393-402
Microbubble contrast agents, 384-391
Micro-computed tomography, 261-268, 345, 346
Micro-positron emission tomography, 10-16, 59, 61, 110
Microsomotic pumps, 121-130
Microultrasound imaging, 289-295
Monocytes, 346
Monomeric red fluorescent protein, 219-227
MRI. See Magnetic resonance imaging
Mucosal perfusion, 345
Multimodality registration, 108-119
Multiple myeloma, 352
Multiple near-infrared molecular probes, 237-245
Multitracer positron emission tomography, 181-191
Muscle LIM protein null mice, 261-268
Nanobodies, 342
Nanoparticles, 1-8, 156-168, 212-218, 277-287, 345, 352
Near-infrared fluorescence imaging, 340, 348
Near-infrared fluorescent dyes, 360
Near-infrared fluorescent transferrin conjugate, 85-94
Near-infrared molecular probes, 237-245
Neurogenesis, 342
Neuroimaging, 341
Neuroinflammation, 344
Nitromidazole, 354
Non-CD4 splenocytes, 369-382
Non-Hodgkin's lymphoma, 355
Obesity, 205-210
Oncology, 340, 349
Optical imaging
of acute myeloid leukemia, 193-203
for drug delivery in oncology, 349
to study estrogen, 363
fluorescent probes, 96-105
immunization by, 301
intravital, 147-155
in vivo, 221-222
multimodality, 353
of multiplexed molecular markers, 366
of neurogenesis, 342
onlinear, 205-210
for solid tumors, 85-94
time domain, 304-313
time-resolved diffuse, 237-245
Oregon Green 488, 247-259
Orthotopic xenografts, 133
Osteoarthritis, 363
Oxygen sensitivity, 219-227
Pancreatic cancer, 131-139
Pancreatic islets, 369-382
Parkinson's disease, 362
Peptides, 171-179, 417-425
Period1 gene, 68-71, 128-130
p53, 346, 354
Phages, 417-425
Phenotyping, 261-268
Phosphatidylserine, 417-425
Photon laser scanning microscopy, 247-259
Pinhole single-photon emission computed
tomography, 346, 350
Planar gamma scintigraphy, 133, 136-139
Plasma membrane, 341
Poly[APMA]-DOTA conjugates, 10-16
Polymerase chain reaction, 58-59, 60-61
Positron emission tomography, 181-191, 340-343, 345, 347-348, 351, 353-354, 359, 367
pQHNIG70 retroviral vector, 405, 407-413
Prostate cancer, 349, 351
magnetic nanoparticles for imaging, 277-287
radionuclide therapy of, 10-16
Protamine, 1-8
Proteinase-modulated contrast agents, 393-402
Protein kinase A, 348
Prussian blue-positive cells, 212-218
Quantum dots, 341
Radioiodination, 132
Radiolabeled G protein, 342
Radiolabeling, 57-58
Radioligands, 344, 359
Radionuclide therapy, 10-16
RAFT. See Regioselectively addressable functionalized template
Reflectance spectrophotometry, 345
Regioselectively addressable functionalized template (RAFT), 43-54
Renal function, 343
Renal ischemia-reperfusion injury, 304-313
Renilla luciferase, 219-227, 323-329
Reperfusion, 156-168, 342, 343
Reporter genes, 219-227
RGD peptides, 43-54
Rhodamine-labeled superparamagnetic liposomes, 140-145
Ribonucleic acid, 357
Saturation binding assay, 58, 60
Scatter analysis, 365
Scintigraphy, 355
Selectin, 348
Serum albumin, 356
Single point time, 315-322
64Cu radionuclide, 10-16
Small interfering ribonucleic acid, 343
Solid tumor xenografts, 85-94
Solubility switch, 393-402
Somatostatin receptor subtype 2, 56-66
Somatostatin receptor type 2, 427-435
SPECT-CT, 134, 136-139
Spectral fluorescence imaging, 269-276
Spinocerebellar ataxias, 346-347
SPIONs. See Superparamagnetic iron oxide nanoparticles
Sponge matrices, 323-329
Stem cells, 342, 344, 347, 362
Stroke, 362
Superparamagnetic iron oxide
anoparticles (SPIONs), 156-168, 212-218
Suvmax, 355
T cells, 96-105, 345, 369-382
Thymidine kinase, 219-227
Thyroid, 348, 364, 366
Time-domain fluorescence imaging, 196, 307-309
Time domain optical imaging, 304-313
Time-resolved diffuse optical imaging, 237-245
Transfection agents, 1-8
Transferrin receptor, 86
Transient bilateral carotid artery
occlusion, 156-168
Translational research, 345
Traumatic brain injury, 348
Tumor(s)
abnormal vasculature in, 351
angiogenesis, 289-295, 331-338, 344
bioluminescent imaging of cell growth, 315-322
detecting early responses to therapy, 341
fluorescence lifetime imaging for, 229-235
gliomas, 181-191
green fluorescent protein-expressing lines, 269-276
growth inhibition, 297-303
hypoxia, 219-227, 333
lung, 345
mammary, 331-338
metastases, 353
progression, 350
solid, 85-94, 140-145
stroma, 205-210
targeted therapies, 349, 350, 358
thyroid, 366
versus inflammation imaging, 364
Two-photon laser scanning microscopy, 247-259
Type 1 diabetes, 369-382
Ultrasound, 289-295, 340, 348, 384-391
Vascular endothelial growth factor, 289-295, 331-338
Vascular perfusion, 350
Viruses, 342
Xenografts, 85-94
Zebrafish, 347
Author Index
Abbott, Andrew, 18
Abraham, Ute, 68, 121
Abulrob, Abedelnasser, 304
Achilefu, Samuel, 237
Adolphi, Natalie L., 277
Ageyeva, Lyudmila, 404
Akers, Walter, 237
Anderson, Carolyn J., 56
Anderson, Stasia A., 212
Andrews, Rebecca, 56
Arbab, Ali S., 212
Aton, Sara J., 68
Baba, Shingo, 315
Badea, Cristian T., 261
Bauer, Bernd, 181
Baumann, Ewa, 304
Beattie, Bradley J., 108
Beckham, Joshua T., 331
Belenkov, Alexandre, 193
Beresten, Tatiana, 404
Bhujwalla, Zaver M., 85
Bidaut, Luc, 108
Bisoffi, Marco, 277
Blasberg, Ronald G., 108, 404
Blindauer, Rebecca, 18
Boturyn, Didier, 43
Brûlet, Philippe, 30
Brunette, Eric, 304
Cai, Quan-Yu, 75
Camarillo, Ignacio G., 205
Capala, Jacek, 229
Cecic, Ivana, 219
Chan, Denise A., 219
Che, Jiantu, 404
Cheng, Ji-Xin, 205
Cheng, Linzhao, 315
Chernomordik, Victor, 229
Cheung, Alison M.Y., 289
Cho, Steve Y., 315
Choi, Kyu-Sil, 75
Choi, Yun, 297
Chung, June-Key, 297
Clément, Olivier, 140
Cleutjens, Jack P.M., 247
Colasante, Cesare, 30
Coll, Jean-Luc, 43
Contag, Christopher H., 369
Crooke, Cornelia E., 331
Curie, Thomas, 30
Dayton, Paul A., 384
Dittmar, Claus, 181
Doubrovin, Mikhail, 404
Dow, William C., 383
Dumy, Pascal, 43
Economou, Eleftherios N., 96
Eiblmaier, Martin, 56
Engles, James M., 315
Escher, Alan, 323
Faley, Shannon L., 331
Favrot, Marie-Christine, 43
Feldmann, Georg, 131
Fingleton, Barbara, 393
Finn, Ronald, 404
Förster, Gregor J., 108
Fortin, Jean-Paul, 140
Foss, Catherine A., 131
Foster, F. Stuart, 289
Fournier, Laure, 140
Fox, James J., 131
Fraefel, Cornel, 181
Frank, Joseph A., 212
Gallant, Pascal, 193
Gambhir, Sanjiv Sam, 219
Gandjbakhche, Amir H., 229
Garofalakis, Anikitos, 96
Gazeau, Florence, 140
Gelovani, Juri G., 417
Giaccia, Amato J., 219
Gjertsen, Bjørn Tore, 193
Gore, John C., 393
Govantes, Ricardo, 108
Graba, James, 289
Graves, Edward E., 219
Grichine, Alexeï, 43
Gross, Shimon, 121
Han, Lin, 427
Hassan, Moinuddin, 229
Hedlund, Laurence W., 261
Heiss, Wolf-Dieter, 181
Heneka, Michael T., 181
Herlea, Oana, 18
Herzog, Erik D., 68, 121
Hettiarachchi, Kanaka, 384
Higashikubo, Ryuji, 56
Hildebolt, Charles, 68
Hoffman, Timothy J., 171
Holten, Dewey, 237
Hruban, Ralph, 131
Huang, Shuning, 156
Huff, Terry B., 205
Iacobuzio-Donohue, Christine, 131
Jacobs, Andreas H., 181
Jansen, E. Duco, 331
Jeon, Yong Hyun, 297
Jeong, Jae Min, 297
Jin, Zhao-Hui, 43
Johnson, G. Allan, 261
Jordan, E. Kay, 212
Josephson, Lee, 1
Josserand, Veronique, 43
Kalish, Heather, 212
Kang, Joo Hyun, 297
Kerbel, Robert S., 289
Kern, Scott E., 131
Kim, Chul Woo, 297
Kim, Eun-A, 75
Kim, Hyang-Ok, 75
Kim, Hyun Joo, 297
Kim, Soo-Yeon, 75
Kim, Sun-Hee, 75
Kim, Young R., 156
Kioussis, Dimitris, 96
Koutcher, Jason A., 108
Kuijpers, Marijke J.E., 247
Kummer, Christiane, 181
Kundra, Vikas, 427
Le, Carl H., 108
Le, Thuc T., 205
Lee, Abraham P., 384
Lee, Dong Soo, 297
Lee, Hye-Jin, 75
Lee, Mi-Heon, 369
Lee, Sang Bong, 229
Lee, Wen-Hui, 369
Lepage, Martin, 393
Lesage, Frederic, 237
Lesieur, Sylviane, 140
Li, Alice, 323
Li, Chun, 417
Lindner, Jonathan R., 289
Liu, Chih-Pin, 369
Liu, Christina H., 156
Liu, Philip K., 156
Longo, Marjorie L., 384
Longo, Valerie A., 108
Lorens, James B., 193
Lu, Xin, 10
Lupu, Florea, 18
Ma, Lixin, 171
Mackel, Julie F. Boslego, 261
Mahmood, Umar, 147, 269
Maitra, Anirban, 131
Mamalaki, Clio, 96
Mao, Lan, 261
Martina, Marie-Sophie, 140
Matrisian, Lynn M., 393
McCormack, Emmet, 193
McIntyre, J. Oliver, 393
Megens, Remco T.A., 247
Melchior, Marco, 393
Ménager, Christine, 140
Merkx, Maarten, 247
Meyer, Heiko, 96
Meyer, Laura A., 56
Micklem, David R., 193
Montet, Xavier, 1
Montet-Abou, Karin, 1
Muzik, Otto, 10
Mystry, Bina S., 289
Nichols, Maxine B., 205
Ntziachristos, Vasilis, 96
Ojogho, Okechukwu, 323
oude Egbrink, Mirjam G.A., 247
Oupicky, David, 10
Papamatheakis, Joseph, 96
Parry, Jesse J., 56
Pawelczyk, Edyta, 212
Peng, Fangyu, 10
Pépin, Claude, 393
Pindard, Lars-Erik, 193
Pittet, Mikael J., 269
Piwnica-Worms, David, 68, 121
Pomper, Martin G., 131
Powell, Robert L., 384
Prasanphanich, Adam, 171
Prior, Julie L., 68, 121
Pursley, Randall, 229
Quarles, C. Chad, 393
Ray, Pritha, 219
Razkin, Jesus, 43
Rehrer, Charles W., 205
Retzloff, Lauren, 171
Riley, Jason, 229
Ripoll, Jorge, 96
Rockman, Howard A., 261
Rogers, Buck E., 56
Rogers, Kelly L., 30
Rold, Tammy L., 171
Rosen, Bruce R., 156
Rueckriem, Benedikt, 181
Rueger, Maria Adele, 181
Rychak, Joshua J., 289
Saunders, Debbie, 18
Saxena, Meera T., 68
Schiffers, Paul H.M., 247
Serda, Rita E., 277
Serganova, Inna, 404
Shan, Liang, 85
Shao, Ruping, 417
Shappell, Scott B., 331
Sheth, Rahul A., 147
Sieckman, Gary, 171
Silasi-Mansat, Robert, 18
Silden, Elisabeth, 193
Sillerud, Laurel O., 277
Slaaf, Dick W., 247
Slinn, Jacqueline, 304
Smith, Charles J., 171
Smith, Nataliya, 18
Smith, Paul, 229
Sridhar, Rajagopalan, 85
Stanimirovic, Danica, 304
Sutphin, Patrick D., 219
Takahashi, Keiko, 331
Takahashi, Takamune, 331
Talu, Esra, 384
Tam, Jenny M., 269
Tesiram, Yasvir A., 18
Texier, Isabelle, 43
Tomemori, Takuya, 331
Towner, Rheal A., 18
Upadhyay, Rabi, 147, 269
Van, Yanghao, 369
van Zandvoort, Marc A.M.J., 247
Veerendra, Bhadrasetty, 171
Volkert, Wynn A., 171
Vollmar, Stefan, 181
Wahl, Richard L., 315
Wang, Paul C., 85
Wang, Songping, 85
Weissleder, Ralph, 1, 147, 269
Wen, Xiaoxia, 417
Wienhard, Klaus, 181
Winkeler, Alexandra, 181
Xiong, Chiyi, 417
Yan, Dan, 427
Ye, Zhaohui, 315
Yoon, Kwon-Ha, 75
Yoon, Seong-Eon, 75
You, Yezi, 10
You, Ying, 393
Yu, Ping, 171
Yuan, Jianchao, 10
Yun, Ki-Jung, 75
Zacharakis, Giannis, 96
Zanzonico, Pat B., 108
Zhao, Shukui, 384
Zuppan, Craig W., 323